Cont. Chemicals (506935)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 6/9 suggests moderate financial health, not a severely distressed balance sheet.
• ROE of 12.48% and ROCE of 10.74% show the business has generated positive returns on capital.
• Profit growth of 30% and a PEG of 0.95 indicate earnings momentum, if it can be sustained.
• Book value of ₹22.16 provides some asset support behind the stock.

Concerns

• Latest quarter sales and net profit are both ₹0 crore, implying no current operating activity.
• Sales growth is 0.00%, so the 30% profit growth is not backed by top-line expansion.
• P/E of 28.39 and P/B of 3.23 leave little margin of safety, especially with no dividend.
• Promoter holding and debt-to-equity data are unavailable, limiting transparency on ownership and leverage.

AI Analysis

Let me examine Cont. Chemicals the way I would examine any business: first, is it an honest, understandable enterprise with a durable moat? Here, the latest quarter reports sales of ₹0 crore and net profit of ₹0 crore. A business generating no current revenue cannot be valued with confidence, and it certainly has no visible moat. The market cap is only ₹17 crore, making it a microcap, but small size is not a virtue; at ₹71.50 the P/E is 28.39 and P/B is 3.23. Book value of ₹22.16 means I am paying over three times book for a company whose sales growth is 0.00%. There is no dividend to reward a patient shareholder. The 30% profit growth is interesting, but not when sales are flat; earnings growth divorced from sales is often one-off or accounting-driven. The so-called PEG of 0.95 is misleading. The Piotroski F-score of 6/9 is an okay indicator, and ROE of 12.48% with ROCE of 10.74% show the business has earned decent returns in the past. Yet I have no promoter holding data and no debt-to-equity information, so I cannot assess management alignment or balance-sheet risk. Graham would ask where the margin of safety is. At 3.23 times book and 28 times earnings, with no current revenue, I do not see one. This is not a fast grower or a stalwart; it is a possible turnaround or special situation. The intelligent investor can wait for evidence that the engine is running again. I would keep this on my watchlist, not in my portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer